Veritas Capital (“Veritas”), a leading investor at the intersection of technology and government, today announced the final close of The Veritas Capital Fund IX (“Fund IX”) with $14.4 billion in aggregate capital commitments. Fund IX was significantly oversubscribed, with demand exceeding the hard cap and surpassing the initial target of $13 billion. The fundraise represents a 35% increase over Fund VIII which closed at $10.7 billion in 2022. With the close of Fund IX, Veritas now manages more ...

Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced a new mobile-focused Server-to-Server (S2S) integration with Singular, a leading marketing analytics and attribution platform. The integration unifies mobile marketing data with direct-to-consumer web purchases, enabling developers to measure campaign performance and player value more accurately than ever before. This press release features multimedia. View the full releas...

Innorna today announced the completion of enrollment and vaccination in its Phase II clinical trial for IN006, the world’s first bivalent respiratory syncytial virus (RSV) mRNA vaccine currently in development by the company. IN006 is also China's first domestically developed RSV vaccine to enter clinical trials, following IND approval in June 2024. The Phase I trial began with the first subject vaccinated in November 2024. Completion of enrollment and dosing in Phase II marks a milestone tow...

Mirion, a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets, is honored to announce its invitation to attend the 69th International Atomic Energy Agency (IAEA) General Conference. Scheduled for September 15–19 in Vienna, Austria, this annual event brings together key stakeholders from across the globe to discuss issues critical to nuclear safety, security, and peaceful applications of nuclear techno...

Nanochon, a Washington, DC and Baltimore, MD-based orthopedic device biotech company developing an implant for treating articular cartilage defects in the knee, is thrilled to announce that it was granted Health Canada Approval for their first in human clinical trial. The trial will be led by Principal Investigator, Dr. Fathi Abuzgaya, who will collaborate with Sports Medicine Specialists, Drs. Joel Lobo, Kajeandra Ravichandiran and Marcin Kowalczuk as Sub-Investigators, at the Durham Bone &a...

Trilliant, a leading international provider of solutions for advanced metering infrastructure (AMI), smart grid, smart cities and IIoT, continues to focus on enabling utilities and energy organizations in Asia-Pacific (APAC) with more than 13 million smart meters operational or in deployment in the region, and millions more planned through strategic partnerships in areas such as Thailand, Malaysia, Philippines, Indonesia, Japan and India. This latest milestone highlights Trilliant’s commitmen...